Patients allocated to tocilizumab were more likely to be discharged from hospital within 28 days (57% vs 50% rate ratio 1♲2 1♱2-1♳3 p<0♰001). Consistent results were seen in all prespecified subgroups of patients, including those receiving systemic corticosteroids. Overall, 621 (31%) of the 2022 patients allocated tocilizumab and 729 (35%) of the 2094 patients allocated to usual care died within 28 days (rate ratio 0♸5 95% CI 0♷6-0♹4 p=0♰028). The trial is registered with ISRCTN (50189673) and ( NCT04381936).īetween April 23, 2020, and Jan 24, 2021, 4116 adults of 21 550 patients enrolled into the RECOVERY trial were included in the assessment of tocilizumab, including 3385 (82%) patients receiving systemic corticosteroids. The primary outcome was 28-day mortality, assessed in the intention-to-treat population.

A second dose could be given 12-24 h later if the patient's condition had not improved. Those trial participants with hypoxia (oxygen saturation <92% on air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein ≥75 mg/L) were eligible for random assignment in a 1:1 ratio to usual standard of care alone versus usual standard of care plus tocilizumab at a dose of 400 mg-800 mg (depending on weight) given intravenously. This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy ), is assessing several possible treatments in patients hospitalised with COVID-19 in the UK. In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation.

Finding Elizabeth by Taylor Fenner